长效注射帕利皮里棕酸盐治疗神经性厌食症和伴随性自闭症谱系障碍:一个病例报告
Yuhei Mori1, Yuhei Suzuki1, Itaru Miura1
1Department of Neuropsychiatry School of Medicine, Fukushima Medical University Fukushima Japan.
PCN reports : psychiatry and clinical neurosciences
|July 15, 2025
概括
长效注射帕利皮里顿棕酸盐可以有效地管理自闭症谱系障碍 (ASD) 和智力障碍患者的严重神经性厌食症 (AN),改善坚持和稳定性.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经性厌食症 (AN) 与自闭症谱系障碍 (ASD) 共同存在,提出了独特的治疗挑战.
- 认知刚性和不良坚持使AN的药理干预复杂化.
- 对长效注射 (LAI) 抗精神病药物在AN,特别是神经发育障碍的证据是有限的.
研究的目的:
- 报告LAI paliperidone palmitate在患有严重AN,ASD和智力障碍的患者中成功使用的情况.
- 为了评估LAI paliperidone palmitate在治疗不耐药的情况下的疗效和安全性.
主要方法:
- 一个27岁的女性患有严重的AN和ASD的病例报告.
- 在失败的口服抗精神病药物后,启动LAI帕利皮里顿棕酸盐 (每月25-50毫克).
- 三年门诊随访监测精神病和营养稳定性.
主要成果:
- 患者在3年内实现并保持了精神和营养稳定.
- 身体质量指数稳定在24kg/m2左右,没有重新住院治疗.
- 在LAI巴利皮里棕酸盐治疗期间,没有报告严重的不良反应.
结论:
- LAI paliperidone palmitate显示了与ASD并发症和智力障碍治疗不耐治疗的AN的管理潜力.
- 对于缺乏坚持和强迫性特征的患者来说,LAI配方可能会带来务实的好处.
- 需要进一步的研究来评估这种人群的长期安全性和有效性.
相关概念视频
01:28Anorexia Nervosa
195
Anorexia nervosa is a complex and severe eating disorder characterized by an intense fear of weight gain, an unrelenting pursuit of thinness, and a distorted body image. It often leads to dangerously low body weight relative to an individual's age and height. This disorder is marked by significant physical and psychological consequences, making it one of the most life-threatening psychiatric illnesses.
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
195
01:19Autism Spectrum Disorder
340
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
340
01:26Psychosis: Goals of Pharmacotherapy
212
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
212
01:30Bulimia Nervosa
197
Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
197
01:21Antipsychotic Drugs: Typical and Atypical Agents
326
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
326
01:16Insulin: Dosing Regimen and Adverse Effects
263
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
263